From what we have discussed above, a variety of drugs suppressing the NLRP3 inflammasome activation or inhibiting the IL-1β activity may be potential therapies for VMC, while the safety and efficacy of some drugs need further elucidation by more comprehensive animal experiments and clinical trials. Here, NLRP3 is linked to liver mesenchymal hamartoma.